Physician profile
Mark N Berman
NPI 1821095373
$5,950.46
in general payments reported to CMS, 2019-2025
24 companies · $716 in 2025
The $716 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $310 · 2021: $838 · 2022: $1,797 · 2023: $742 · 2024: $1,093 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,550.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $1,099.38 | 2022 | |
| Abbvie INC. | $981.32 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Johnson & Johnson Surgical Vision, INC. | $783.63 | 2019-2024 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Alcon Vision LLC | $565.81 | 2020-2025 | Rhopressa, Clareon, Rocklatan |
| Coopervision INC. | $500.00 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $317.96 | 2022-2025 | Ic-8 Apthera Iol, Vyzulta, Miebo |
| New World Medical,INC. | $246.69 | 2023-2024 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Tarsus Pharmaceuticals, INC. | $211.24 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $171.55 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $153.80 | 2019-2021 | |
| Allergan, INC. | $152.61 | 2019-2021 | |
| Horizon Therapeutics Plc | $141.28 | 2023 | Tepezza |
| Carl Zeiss Meditec, INC. | $134.05 | 2019 | |
| Harrow Eye, LLC | $102.20 | 2024 | Vevye |
| Oyster Point Pharma, INC. | $98.27 | 2022-2024 | Tyrvaya |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $68.58 | 2024-2025 | Tepezza |
| Thea Pharma INC. | $54.86 | 2023 | |
| Dompe US, INC. | $53.36 | 2024-2025 | Oxervate |
| Sandoz INC. | $27.44 | 2024 | Cimerli |
| Kala Pharmaceuticals, INC. | $18.87 | 2021 | |
| Sight Sciences, INC. | $17.79 | 2022 | |
| Aerie Pharmaceuticals, INC. | $17.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.19 | 2019 | |
| Omeros Corporation | $14.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.